Max Nisen, Columnist

Allergan Needs Better Targets

The drugmaker lacks enough reliable sources of near-term growth.

November 4, 2016 at 1:28 PM UTC

Max Nisen is a healthcare analyst at Bloomberg Intelligence. He previously wrote for Bloomberg Opinion, Quartz and Business Insider.

Provide news feedback or report an error

Site feedback:

Take our Survey

This article is for subscribers only.

During Allergan's third-quarter earnings call this week, CEO Brent Saunders told shareholders the best thing the company can do with its cash right now is buy back its own stock.

The shareholder response: Are you sure?